制药

关注
Illustration of a couple in a kitchen reviewing reduced grocery spending after starting Ozempic-like GLP-1 drugs, per Cornell study.
AI 生成的图像

Cornell study links GLP-1 drugs like Ozempic and Wegovy to lower household food spending

由 AI 报道 AI 生成的图像 事实核查

Households that start GLP-1 appetite-suppressing medications such as Ozempic and Wegovy reduce food spending within months, including at grocery stores and limited-service restaurants, according to new research from Cornell University based on linked survey responses and transaction data.

Researchers from Australia have reported positive results from a Phase II clinical trial of a new carbohydrate-based drug for treating sepsis. The trial, involving 180 patients in China, demonstrated the drug's ability to reduce the condition's severity. This development offers hope for the first targeted therapy against a leading cause of global deaths.

由 AI 报道

A Delhi High Court verdict on January 12 has allowed Indian pharma company Zydus Lifesciences to manufacture and sell a biosimilar version of Bristol Myers-Squibb's cancer drug Nivolumab. This ruling could pave the way for more affordable immunotherapy treatments for cancer patients in India. Nivolumab is effective against various cancers, with its patent set to expire in May 2026.

Egypt's Minister of Health and Population, Khaled Abdel Ghaffar, held an expanded meeting on Monday with representatives of relevant state bodies to discuss ways to support pharmaceutical manufacturers and draft a comprehensive policy framework for boosting local production and localizing biopharmaceutical and biological products.

由 AI 报道

第一三共宣布,将于2月2日起开始紧急避孕药Norlevo的非处方销售,这是日本首次无需处方即可购买此类药片。为安全起见,该药片必须在训练有素的药剂师监督下服用。

Chile's Public Health Institute warned of two new risks linked to leuprorelina-containing drugs, used for advanced prostate cancer treatment. These include liver issues like fatty liver and severe skin reactions that can be fatal. The review drew from international evidence, with no local cases reported in the past 12 years.

由 AI 报道

The RD Saúde group, owner of the Raia and Drogasil chains, obtained a license to produce and sell over 20 molecules of over-the-counter medicines starting in 2026. The initiative was announced during the RD Day in São Paulo. The products will be launched under the Bwell brand.

 

 

 

此网站使用 cookie

我们使用 cookie 进行分析以改进我们的网站。阅读我们的 隐私政策 以获取更多信息。
拒绝